Absci Corp
NASDAQ:ABSI

Watchlist Manager
Absci Corp Logo
Absci Corp
NASDAQ:ABSI
Watchlist
Price: 3.16 USD 4.64% Market Closed
Market Cap: $475.2m

Operating Margin

-4 261.1%
Current
Declining
by 2 006.8%
vs 3-y average of -2 254.3%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-4 261.1%
=
Operating Income
$-120m
/
Revenue
$2.8m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-4 261.1%
=
Operating Income
$-120m
/
Revenue
$2.8m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Absci Corp
NASDAQ:ABSI
473.2m USD
Loading...
US
PerkinElmer Inc
LSE:0KHE
1.3T USD
Loading...
US
Thermo Fisher Scientific Inc
NYSE:TMO
241.5B USD
Loading...
US
Danaher Corp
NYSE:DHR
169.6B USD
Loading...
KR
Samsung Biologics Co Ltd
KRX:207940
83.2T KRW
Loading...
CH
Lonza Group AG
SIX:LONN
37.8B CHF
Loading...
US
IQVIA Holdings Inc
NYSE:IQV
40.7B USD
Loading...
CN
WuXi AppTec Co Ltd
SSE:603259
280.3B CNY
Loading...
US
Agilent Technologies Inc
NYSE:A
39.3B USD
Loading...
US
Mettler-Toledo International Inc
NYSE:MTD
29.4B USD
Loading...
FR
Sartorius Stedim Biotech SA
PAR:DIM
20.2B EUR
Loading...

Market Distribution

Lower than 95% of companies in the United States of America
Percentile
5th
Based on 14 112 companies
5th percentile
-4 261.1%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Absci Corp
Glance View

Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. The company is headquartered in Vancouver Washington, Washington and currently employs 216 full-time employees. The company went IPO on 2021-07-22. The firm has developed an Integrated Drug Creation platform to identify novel drug targets, discover biotherapeutic candidates, and generate the cell lines to manufacture them in a single process. The company uses synthetic biology technologies and deep learning artificial intelligence (AI) to predict, identify, design, construct, screen, select and scale production of biologic drug candidates, and learn from the data it generates. The firm has drug candidates in approximately nine active programs, eight of the active programs are focused on developing production cell lines for drug candidates that the Company's partners are developing. The company has one discovery program, focused on lead optimization with Astellas. The Company’s active programs include Bispecific monoclonal antibodies (mAb), Bispecific T-cell engager, Cytokine, Fab, Multivalent Fc-fusion, Plasma protein and mAb.

ABSI Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-4 261.1%
=
Operating Income
$-120m
/
Revenue
$2.8m
What is Absci Corp's current Operating Margin?

The current Operating Margin for Absci Corp is -4 261.1%, which is below its 3-year median of -2 254.3%.

How has Operating Margin changed over time?

Over the last 3 years, Absci Corp’s Operating Margin has decreased from -1 973.8% to -4 261.1%. During this period, it reached a low of -4 261.1% on Sep 30, 2025 and a high of -1 110.9% on Jun 30, 2023.

Back to Top